🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 18 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 21/09/1995 | 9,75 | 9,75 | 9,50 | 9,66 | -2,21% | 2,56% | 495.200 |
| 20/09/1995 | 10,13 | 10,13 | 9,50 | 9,88 | -1,25% | 6,17% | 426.000 |
| 19/09/1995 | 10,13 | 10,13 | 9,75 | 10,00 | +2,56% | 3,70% | 59.600 |
| 18/09/1995 | 10,00 | 10,13 | 9,75 | 9,75 | -1,27% | 3,75% | 21.200 |
| 15/09/1995 | 9,88 | 9,88 | 9,63 | 9,88 | +1,77% | 2,53% | 127.200 |
| 14/09/1995 | 9,88 | 9,88 | 9,63 | 9,70 | +0,16% | 2,53% | 207.800 |
| 13/09/1995 | 10,13 | 10,13 | 9,63 | 9,69 | -3,13% | 4,94% | 190.000 |
| 12/09/1995 | 10,13 | 10,38 | 9,88 | 10,00 | -1,84% | 4,94% | 41.400 |
| 11/09/1995 | 10,75 | 10,75 | 10,13 | 10,19 | -4,12% | 5,81% | 96.400 |
| 08/09/1995 | 11,00 | 11,13 | 10,63 | 10,63 | -1,16% | 4,55% | 149.200 |
| 07/09/1995 | 11,25 | 11,63 | 10,75 | 10,75 | -5,49% | 7,78% | 87.600 |
| 06/09/1995 | 11,63 | 11,63 | 11,25 | 11,38 | -1,09% | 3,23% | 74.400 |
| 05/09/1995 | 11,00 | 11,50 | 11,00 | 11,50 | +2,22% | 4,55% | 132.000 |
| 01/09/1995 | 10,38 | 11,25 | 10,38 | 11,25 | +8,43% | 8,43% | 146.200 |
| 31/08/1995 | 10,25 | 10,75 | 10,00 | 10,38 | +3,75% | 7,32% | 245.200 |
| 30/08/1995 | 9,13 | 10,25 | 9,13 | 10,00 | +8,11% | 12,33% | 486.800 |
| 29/08/1995 | 9,25 | 9,63 | 9,13 | 9,25 | -1,33% | 5,41% | 43.600 |
| 28/08/1995 | 9,50 | 9,75 | 9,38 | 9,38 | -2,60% | 3,95% | 89.800 |
| 25/08/1995 | 9,88 | 9,88 | 9,38 | 9,63 | +0,00% | 5,06% | 121.600 |
| 24/08/1995 | 9,94 | 10,25 | 9,63 | 9,63 | -3,75% | 6,29% | 107.600 |
| 23/08/1995 | 9,94 | 10,13 | 9,94 | 10,00 | -1,23% | 1,89% | 88.400 |
| 22/08/1995 | 9,94 | 10,25 | 9,94 | 10,13 | +0,00% | 3,14% | 175.600 |
| 21/08/1995 | 10,25 | 10,25 | 9,94 | 10,13 | -1,22% | 3,05% | 108.800 |
| 18/08/1995 | 10,38 | 10,38 | 9,88 | 10,25 | -1,20% | 4,82% | 127.000 |
| 17/08/1995 | 10,38 | 10,50 | 10,00 | 10,38 | +3,11% | 4,82% | 181.200 |
| 16/08/1995 | 9,88 | 10,25 | 9,63 | 10,06 | +1,90% | 6,33% | 265.400 |
| 15/08/1995 | 9,50 | 9,88 | 9,50 | 9,88 | +3,27% | 3,95% | 193.200 |
| 14/08/1995 | 9,50 | 9,63 | 9,13 | 9,56 | +3,38% | 5,26% | 233.800 |
| 11/08/1995 | 9,75 | 9,75 | 9,13 | 9,25 | +1,37% | 6,41% | 281.800 |
| 10/08/1995 | 9,47 | 9,50 | 9,13 | 9,13 | -3,95% | 3,96% | 113.800 |